Tenax Therapeutics holder updates 3.3% equity stake

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander via Amendment No. 1 to a Schedule 13G. The reporting group discloses beneficial ownership of 876,230 shares of Tenax common stock, representing 3.3% of the class.

The shares are reported with shared voting and dispositive power and no sole voting or dispositive power. The filing notes that the securities are held by entities over which the Millennium entities and Mr. Englander have voting control and investment discretion, and it states that this should not, by itself, be construed as an admission of beneficial ownership. The group confirms ownership of 5 percent or less of the class.

Key Figures

Shares beneficially owned: 876,230 shares Percent of class: 3.3% Sole voting power: 0 shares +3 more

6 metrics

Shares beneficially owned 876,230 shares Common stock of Tenax Therapeutics reported by each of the three reporting persons

Percent of class 3.3% Percentage of Tenax Therapeutics common stock beneficially owned by the reporting persons

Sole voting power 0 shares Shares over which the reporting persons have sole power to vote

Shared voting power 876,230 shares Shares over which the reporting persons have shared power to vote

Sole dispositive power 0 shares Shares over which the reporting persons have sole power to dispose

Shared dispositive power 876,230 shares Shares over which the reporting persons have shared power to dispose

Key Terms

beneficially owned, shared voting power, shared dispositive power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: See response to Item 9 on each cover page."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"6 | Shared Voting Power 876,230.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"8 | Shared Dispositive Power 876,230.00"

Schedule 13G regulatory

"The securities disclosed herein as potentially beneficially owned ... Schedule 13G."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Joint Filing Agreement regulatory

"Exhibit I: Joint Filing Agreement, dated as of July 16, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in TENX is reported by Millennium Management LLC?

Millennium Management LLC and related filers report beneficial ownership of 876,230 shares of Tenax Therapeutics (TENX) common stock, representing 3.3% of the outstanding class, with shared voting and dispositive power over those shares.

Does the Millennium group own more than 5% of Tenax Therapeutics (TENX)?

No. The filing explicitly states that the reporting persons have ownership of 5 percent or less of the Tenax Therapeutics common stock class, with a disclosed percentage of 3.3% of the outstanding shares.

Who are the reporting persons in this Schedule 13G/A for TENX?

The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, who together report shared voting and dispositive power over 876,230 shares of Tenax Therapeutics common stock.

What type of power over TENX shares does the Millennium group report?

They report 0 shares with sole voting or dispositive power and 876,230 shares with shared voting and shared dispositive power, reflecting control exercised through affiliated investment entities.

Does Israel A. Englander personally admit beneficial ownership of TENX shares?

The filing states the securities are held by entities subject to voting control and investment discretion of the reporting persons and notes that this should not be construed, by itself, as an admission of beneficial ownership by any of them.

What agreement accompanies this TENX Schedule 13G/A amendment?

An exhibit titled Joint Filing Agreement dated July 16, 2026, is included, confirming that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander are jointly filing this ownership report for Tenax Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:58 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Tenax Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

88032L605

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 876,230.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 876,230.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

876,230.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 876,230.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 876,230.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

876,230.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 876,230.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 876,230.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

876,230.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tenax Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 88032L605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/16/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/16/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	07/16/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of July 16, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.